HealthQuill Drugs
Gram-negative, Chlamydia psittaci bacteria
Drugs Health Medical

Chlamydia vaccine shows promise in initial trials

HQ Team April 12, 2024: An early-stage clinical trial for a chlamydia vaccine has shown some positive results, according to a report published.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.
Drugs Medical Pharma

FDA’s accelerated approval of cancer drugs is hasty and doubtful, says new report

HQ Team April 10, 2024:  A new study has found that cancer drugs that got accelerated approval under the US Federal Drug Approval.

Read More
Synchron, a US-based brain implant company, plans to recruit motor-impaired patients for its clinical trial in competition with Elon Musk’s Neurolink.
Drugs Health Pharma

Rivalling Elon Musk’s Neurolink, Synchron plans brain implant trial 

HQ Team April 9, 2024: Synchron, a US-based brain implant company, plans to recruit motor-impaired patients for its clinical trial in competition with.

Read More
Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to 59 years has met its primary goals in trials.
Drugs Health Pharma

Last-stage trials achieve “positive” results for RSV drug: Pfizer says

HQ Team April 9, 2024: Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to.

Read More
endometriosis
Drugs Health Medical

Oral spray vaccine offers long-term relief against recurrent UTIs

HQ Team April 8, 2024: An oral spray vaccine has proved effective in halting recurrent Urinary Tract Infections (UTIs) for up to nine.

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Health Medical

Rapid cellular aging reason behind early-onset cancers: Scientists

HQ Team April 8, 2024: More cancer cases are being detected among the younger generation, according to a new study presented at the.

Read More
Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the marketing authorisations for its amyotrophic lateral sclerosis (ALS) therapy after the drug failed in a last-stage trial.
Drugs Health Pharma

Amylyx Pharma pulls out ALS therapy drug from US, Canada

HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.

Read More
Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex's planned acquisition of Femoston and Duphaston stating it may reduce competition and choice for hormone replacement therapy (HRT) treatments in the country.
Drugs Health Pharma

Britain’s CMA raises concern over Theramex’s Femoston buy

HQ Team April 4, 2024: Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex’s planned acquisition of Femoston and Duphaston stating it.

Read More
The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults. 
Drugs Health Pharma

Swiss-based Basilea Pharmaceutical’s antimicrobial drug gets FDA nod 

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

Read More
Humans’ lack of immunity may rapidly result in the transmission of bird flu among people if the avian influenza virus acquires the ability to spread quickly, according to the European Food Safety Authority (EFSA). 
Drugs Health Pharma

EFSA issues warning on bird flu spread, says humans lack immunity  

HQ Team April 3, 2024: Humans’ lack of immunity may rapidly result in the transmission of bird flu among people if the avian.

Read More